Description
5-Amino-1MQ (5-Amino-1-methyl-quinolinium) is a selective inhibitor of nicotinamide N-methyltransferase (NNMT). NNMT is an enzyme strongly expressed in adipose tissue and liver that methylates nicotinamide to N-methyl-nicotinamide. In obesity models NNMT is upregulated and appears causally involved in insulin resistance and obesity.
Per study reports 5-Amino-1MQ selectively blocks NNMT. The consequence: nicotinamide and SAM (S-adenosyl-methionine) are preserved, methyl-group balance in adipose tissue is normalized. In the landmark Brenner lab studies (Neelakantan et al 2018) 5-Amino-1MQ showed significant fat loss in diet-induced obesity in mice without food reduction and without lean mass loss.
This makes the compound particularly interesting per study reports: no stimulant, no cardiac stress like under Clenbuterol, no thyroid hormone suppression like under T3, no narrow safety window like under DNP. The mechanism targets a specific obesity-relevant metabolic pathway.
A second property: 5-Amino-1MQ appears to support muscle regeneration. In studies on older mice the compound improved stem cell function in skeletal muscle and fiber type preservation.
Pharmacokinetics in human models aren’t fully characterized yet. Mouse data show oral availability with several-hour half-life, daily dosing typical.
You can order 5-Amino-1MQ as oral tablets in one bottle with 50mg per tablet.
This information is for research and educational purposes only. No medical recommendations.
Risks & Safety
5-Amino-1MQ sits in the mid range of the risk scale and is considered relatively mild compared to stimulants or thyroid hormones - the limiting factor is the thin human data situation.
Documented in studies and the literature:
- Limited human data: pharmacokinetics in human models are not yet fully characterized. The bulk of the data comes from mouse studies.
- No stimulant profile: unlike Clenbuterol, the NNMT inhibitor causes no direct cardiac stress in available data.
- No narrow safety window: in contrast to DNP, the mechanism targets a specific metabolic pathway without the acute toxicity issue.
- No long-term data: robust long-term human studies do not exist.
Monitoring via bloodwork is recommended. This classification does not replace medical advice. Risk and responsibility for any actual use lie entirely with the buyer.
Studies
- Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice - Biochemical Pharmacology 2018, Neelakantan et al: original study, documents the reduction of body weight and white adipose mass through NNMT inhibition in an animal model.
- A small molecule inhibitor of Nicotinamide N-methyltransferase for the treatment of metabolic disorders - Scientific Reports 2018, Kannt et al: characterization study of an NNMT inhibitor and its metabolic effects.
- Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice - Scientific Reports 2022, Dimet-Wiley et al: animal study on the combination of calorie reduction and NNMT inhibition.
- Nicotinamide N-methyltransferase (NNMT): a novel therapeutic target for metabolic syndrome - Frontiers in Pharmacology 2024, Sun et al: recent review of the role of NNMT as a metabolic research target.
